Latest news
MACE Risk May Be Reduced with GLP-1 Drug in High-Risk Patients - insideprecisionmedicine.cominsideprecisionmedicine.com · Fri, 07 Aug 2026 00:54:43 GMTZEUS Trial: Ziltivekimab Fails to Reduce MACE in ASCVD Patients - TCTMD.comTCTMD.com · Mon, 03 Aug 2026 17:05:08 GMTNovo Nordisk’s mAb for MACE risk reduction fails in Phase III trial - Clinical Trials ArenaClinical Trials Arena · Fri, 31 Jul 2026 15:22:14 GMTZiltivekimab Fails to Reduce MACE Risk in Phase 3 ZEUS Trial - HCPLiveHCPLive · Fri, 31 Jul 2026 12:42:48 GMTNovo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline - CNBCCNBC · Fri, 31 Jul 2026 11:39:14 GMTZiltivekimab shows no MACE risk reduction in ZEUS trial for Novo Nordisk (NVO) - Stock TitanStock Titan · Fri, 31 Jul 2026 07:00:00 GMT